• P A Singer, E C Thiel, I Salit, W Flanagan, and C D Naylor.
• University of Toronto Joint Centre for Bioethics, Department of Medicine, University of Toronto, Canada.
• J Gen Intern Med. 1997 Dec 1; 12 (12): 729735729-35.

ObjectiveTo determine whether persons living with HIV find a disease-specific advance directive more acceptable than a generic directive.DesignRandomized clinical trial.SettingHIV consumer organization and hospital-based HIV clinic.ParticipantsVolunteer sample of persons with HIV.InterventionsThe disease-specific HIV Living Will, the generic Centre for Bioethics Living Will, or both.Measurements And Main ResultsOf 101 participants who received both advance directives, 78 (77.2%) preferred the disease-specific HIV Living Will and 23 (22.8%) preferred the generic Centre for Bioethics Living Will (p < .001). Most participants who preferred the HIV Living Will did so because it was more specific or relevant to their situation.ConclusionsPersons living with HIV prefer a disease-specific to a generic advance directive. They should be offered a disease-specific advance directive. Our findings should also encourage investigators to develop and evaluate disease-specific advance directives in other clinical settings.

9 keywords...

hide…